Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,378 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Monoclonal Antibody Clear all
Active, not recruiting Phase 2 Interventional

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Terminated Not applicable Interventional Results available

Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9

NCT00582608
View directory record Official record
Conditions
CNS Cancer, Neuroblastoma, Sarcoma
Interventions
131I-8H9, 8H9
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 1 Interventional

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

NCT06826768
View directory record Official record
Conditions
Prostate Cancer
Interventions
REGN5678, Cemiplimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

NCT01757197
View directory record Official record
Conditions
Glucocorticosteroid Refractory Acute GVHD
Interventions
Toclizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jun 26, 2026, 10:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

NCT05996523
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions
PRGN-2009, Pembrolizumab, EKG, CT, PET scan, MRI, Biopsy
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

NCT05060432
View directory record Official record
Conditions
Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
Interventions
EOS-448, pembrolizumab, inupadenant, Dostarlimab, SOC chemotherapies
Drug
Lead sponsor
iTeos Belgium SA
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Diego, California • Bergen, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission

NCT00002458
View directory record Official record
Conditions
Neuroblastoma
Interventions
monoclonal antibody 3F8
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

NCT00005616
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
conventional surgery, neoadjuvant therapy, radionuclide imaging, iodine I 131 monoclonal antibody F19
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants

NCT00636285
View directory record Official record
Conditions
Staphylococcal Sepsis
Interventions
Placebo, BSYX-A110
Drug
Lead sponsor
Biosynexus Incorporated
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)

NCT01589185
View directory record Official record
Conditions
Pneumonia Due to Staphylococcus Aureus
Interventions
KBSA301, Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jun 26, 2026, 10:50 AM EDT
Active, not recruiting Phase 1 Interventional

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT05139004
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate, Indium In 111-DOTA-Basiliximab, Melphalan, Palifermin, Total Lymphoid Irradiation, Total Marrow Irradiation, Yttrium Y 90 Basiliximab
Procedure · Biological · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jun 26, 2026, 10:50 AM EDT
Terminated Phase 3 Interventional Results available

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02785900
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
33A, placebo, azacitidine, decitabine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
40
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions
BNT323, BNT327
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

NCT00936936
View directory record Official record
Conditions
Testicular Cancer
Interventions
Gemcitabine, Docetaxel, Melphalan, Carboplatin, Mesna, Ifosfamide, Etoposide, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

NCT01968109
View directory record Official record
Conditions
Neoplasms by Site
Interventions
Relatlimab, Nivolumab, BMS-986213
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • Tampa, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)

NCT03729752
View directory record Official record
Conditions
HIV-1-infection
Interventions
[89]Zr-DFO-VRC-HIVMAB060-00-AB
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 26, 2026, 10:50 AM EDT
Not listed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy

NCT00066547
View directory record Official record
Conditions
Breast Cancer
Interventions
monoclonal antibody HuHMFG1
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jun 26, 2026, 10:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

NCT02205333
View directory record Official record
Conditions
Advanced Solid Tumors, Aggressive B-cell Lymphomas
Interventions
MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab, MEDI6469 Plus Durvalumab, MEDI6469 plus Rituximab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

NCT01025206
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BI-505
Biological
Lead sponsor
BioInvent International AB
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Jun 26, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

NCT01009281
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Bristol, Connecticut • Great Neck, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

NCT00719212
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479
Biological
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Bakersfield, California • Fullerton, California • La Verne, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

NCT00147537
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871, paclitaxel, carboplatin, erlotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
26
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00657007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab, Placebo
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jun 26, 2026, 10:50 AM EDT